Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Minneapolis, Minnesota


To evaluate and compare the effects on safety measures and clinical chemistry after BLI800 in two groups of patients and one group of healthy controls. The patient groups will be those with mild or moderate hepatic impairment or moderate renal disease.


Inclusion Criteria: - Are male or female adults who are: - With Child-Pugh Hepatic Dysfunction Stage A or B, or - With Moderate Renal Disease or - Healthy subjects matched to those who are enrolled in this study - Subjects who are considered to have only clinically non-significant conditions, as judged by the Principal Investigator and based on physical examination, laboratory profiles, medical history and ECG. - Female subjects who are not surgically sterile (i.e., having had a hysterectomy, bilateral oophorectomy or tubal ligation) or who are not at least 2 years naturally postmenopausal must agree to use an acceptable form of contraception. - Provide voluntary consent in writing to participate in this study. Exclusion Criteria: - Subjects with known or suspected ileus, severe ulcerative colitis, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, or megacolon. - Subjects with impaired consciousness that predisposes them to pulmonary aspiration. - Subjects who, in the opinion of the Principal Investigator, have uncontrolled clinically significant pre-existing electrolyte disturbances, based on the Screening visit laboratory results. - Subjects with present or prior NYHA Functional Classification grade III or IV congestive heart failure. - Subjects who are pregnant or lactating, or intending to become pregnant during the study. - Subjects of childbearing potential who refuse a pregnancy test. - Subjects who have participated in an investigational clinical, surgical, drug, or device study within the past 30 days. - Subjects with a history of allergic or adverse response to any BLI-800 component. - Subjects who donated more than one pint of blood within 30 days prior to the study. - Subjects who donated plasma within 7 days prior to the study. - Subjects who had an abnormal diet or substantial changes in eating habits within 30 days prior to the start of the study. - Subjects who have had a bowel cleansing procedure within the past month or who have taken a laxative within the 5 days (120 hours) prior to dosing or who require a laxative every day. - Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures.



Primary Contact:

Study Director
Russell Pelham, Ph.D.
Braintree Laboratories, Inc.

Backup Contact:


Location Contact:

Minneapolis, Minnesota
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: February 04, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.